-
Views
-
Cite
Cite
Jean L. Grem, Susan A. King, Robert E. Wittes, Brian Leyland-Jones, The Role of Methotrexate in Osteosarcoma, JNCI: Journal of the National Cancer Institute, Volume 80, Issue 9, 6 July 1988, Pages 626–655, https://doi.org/10.1093/jnci/80.9.626
- Share Icon Share
Abstract
High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626–656]
This content is only available as a PDF.
© Oxford University Press
Issue Section:
Review
You do not currently have access to this article.